Citations

Showing 10 of 108104 citations.

Abstract 341: Optimizing Cardiovascular Disease Research in Women
Wenger, Nanette K. , Taylor, Doris A. , Kaplan, Jay R. , Rich‐Edwards, Janet W. , Miller, Virginia M. , Shaw, Leslee J. , Berga, Sarah L. , Webb, Clinton, Ouyang, Pamela , Reckelhoff, Jane F. , Steiner, Meir , Merz, C. Noel Bairey

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.341 Get It

Cardiovascular (CV) disease (CVD) is the major health burden and cause of death for women. Marked disparities exist in CVD diagnosis, prevention, and treatment between women and men – as well as lack of female-specific data. Population, physiologic, translational, and clinical trial studies of sex and gender differences in CVD [[Unable to Display Character: –]] even when only women are studied[[Unable to Display Character: –]] often do not collect relevant data specific to women that could inform study outcomes. The ISIS CVD Network of the Society for Women’s Health Research compiled an inventory of items specific for women across the lifespan, together with references for methods and strategies to gather and evaluate this information; some items comprise robust measures, others are in development. The objective is to enhance usefulness of CVD research data in understanding sex and gender differences, thereby optimizing healthcare delivery and outcomes for women. Included are hormonal variables (menstrual cycle phase, hormone levels) oral contraceptive use, pregnancy history/complications, polycystic ovary syndrome (PCOS) components, measures of menopause, and menopausal hormone therapy, variables generally not collected in research studies, but essential to determine their role as sex-specific contributors to CV health and disease. Clear associations exist between reproductive health and CV health and disease. For example 25-33% of women experience complications of pregnancy that may precede and predispose to CVD. Vascular complications during pregnancy, antecedent risk factors and subsequent clinical CVD can be ascertained using medical records, birth registries, and/or maternal recall. Evaluating compilations of patient data with known hormonal or menopausal status using reference standards and patient data for PCOS could inform relationships to subsequent CV outcomes. Variables predominant among women that preferentially disadvantage them should be considered; e.g. psychosocial issues and elderly age. Depressive disorders are twice as common among women as men. They adversely affect CVD outcomes in women, yet the effect of reproductive life cycle and of hormonal fluctuations on depression and etiologic contributions of depression to CVD are inadequately explored. In addition to traditional CVD risk factors, diabetes mellitus, chronic inflammatory disorders, oxidative stress, vasomotor dysfunction, coronary microvascular disorders, and other novel risk variables that preferentially impact women should be explored. Along with increased enrollment of women in CVD research studies and analysis of clinical and genetic studies by sex, improvements and expansion of study design must include these understudied uniquely or predominantly female characteristics. This will enhance the quality and quantity of evidence-based medicine to guide CVD care in women and men thereby setting the stage for personalized approach to medicine.
Abstract 332: Association of Body Mass Index with Health Status Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Sharma, Praneet, Kureshi, Faraz , Buchanan, Donna M., Jayaram, Natalie , Grodzinsky, Anna , Salisbury, Adam C. , Fendler, Timothy J. , Tang, Fengming, Ting, Henry H. , Merrill, Eric Dean , Spertus, John A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.332 Get It

Background: An obesity paradox, with better long-term survival in obese patients undergoing percutaneous coronary intervention (PCI), has been well described. The association between obesity and health status outcomes after PCI is unknown. Methods: We prospectively enrolled 3,281 PCI patients in a 10-center observational cohort study and categorized their body mass index (BMI) into normal (18.5 to <25), overweight (25 to <30), obese (30 to <35) and morbidly obese (≥ 35).Generalized linear models were used to describe the association between BMI and health status measures at 6 & 12 months, after adjusting for baseline characteristics and health status scores. Health status outcomes included; Seattle Angina Questionnaire [SAQ] Angina Frequency (AF), and Quality of Life (QL) scores, as well as the EQ-5D visual analogue scale (EQ-5D VAS). Interaction with time was not significant, so an estimate of the average benefit over time was generated. Results: The distribution of patients’ BMI revealed that 17% were normal, 35% overweight, 28% obese and 20% morbidly obese. Compared with normal weight patients, morbidly obese individuals were younger (mean 60.8 yr vs. 67.9 yr) and had a higher prevalence of diabetes, hypertension and heart failure. They underwent radial artery access (12.0% vs. 7.0%) and drug eluting stent implantation (80.4% vs. 76.0%) more frequently. Unadjusted changes in scores were lower (worse) among morbidly obese as compared with normal weight patients for SAQ AF (mean difference [MD] -1.52; 95% Confidence Interval [CI] -3.05, -0.02), SAQ QL (MD -2.51; CI -4.48, -0.54), and EQ-5D VAS (MD -5.74;CI -7.52, -3.96). After adjustment, these differences were no longer significantly different for SAQ AF and SAQ QL (figure), although EQ-5D VAS scores remained lower among obese and morbidly obese patients. Conclusion: The overall health status was mildly worse among obese and morbidly obese individuals after PCI, but the benefits of PCI on patients’ disease-specific health status were similar across weight categories. This suggests that PCI is equally effective in improving angina and disease-specific quality of life, independent of patients’ weight.
Abstract 318: Caregiver Experiences with Decision Making in Destination Therapy Left Ventricular Assist Devices: A Qualitative Study
Jones, Jacqueline , Nowels, Carolyn T., McIlvennan, Colleen Kelley , Allen, Larry A. , Lindenfeld, JoAnn , Swetz, Keith M. , Matlock, Daniel D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.318 Get It

BACKGROUND: Destination therapy left ventricular assist device (DT LVAD) is increasingly offered to patients with end-stage heart failure who are ineligible for heart transplantation. Implanting centers often require the identification of a dedicated caregiver prior to DT LVAD implantation; however, the caregiver experience surrounding this difficult decision is relatively unexplored. METHODS: Between October 2012 and July 2013, we conducted semi-structured, in-depth interviews of caregivers to understand their experiences with decision making for loved ones considering and living with DT LVADs. Data were analyzed using a mixed inductive and deductive approach. RESULTS: We interviewed 17 caregivers: 16 caregivers of patients who had received a DT LVAD and 1 caregiver of a patient who had declined a DT LVAD. At the time of the caregiver interview, 10 DT LVAD patients were living and 7 were deceased. The majority were women (n=16) of whom 12 were either spouses or widows of the patients. Median age of caregivers was 65 (range 35-79). Twelve caregivers reported spending more than 8 hours per week caring for their loved one, and 14 attended regular medical appointments. Throughout the interviews, caregivers reported that DT LVAD was a complex decision making process with many inherent tensions. The themes identified are broadly interpreted under three domains: 1) the stark decision context with tension between hopes and realities, “when we first started out¼we had hopes of a transplant¼but once the lung function was done, and the kidneys ¼there was pretty much nothing. There was no hope other than the LVAD”; 2) the challenging decision process and the tension between wanting their loved ones to live, “I said ‘Well, I'll tell you what. I didn't marry you to be a young widow” and wanting to respect their loved ones’ wishes, “My thoughts were this was his life and it was his choice”; and 3) the downstream decision outcome and the tension between gratitude, “I'm just thankful to have my dad here¼” and a feeling of burden, “I've never felt caregiver was my gift¼I tend to feel like I'm being imposed upon at times.” CONCLUSIONS: Despite the promise of significantly improved survival for some patients, DT LVAD has major implications for caregives as well as patients. Decision making surrounding DT LVAD requires education of both the patient and caregiver of potential stresses. Additionally, decision-making surrounding DT LVAD should seek to incorporate decision support for patients and caregivers. This should include a focus on caregiver burden and the tensions that caregivers may experience.
Abstract 27: Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction
Kureshi, Faraz , Kennedy, Kevin F. , Jones, Philip G. , Buchanan, Donna M., Sharma, Praneet, Fendler, Timothy J. , Nallamothu, Brahmajee K. , Thomas, Randal J. , Arnold, Suzanne V. , Ho, P. Michael , Spertus, John A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.27 Get It

Background: Cardiac rehabilitation (CR) is a class Ia recommendation and endorsed performance measure for the quality of care in acute myocardial infarction (AMI) survivors. While participation in CR after AMI is associated with reduced mortality, conflicting data exists on its association with health status outcomes. Methods: Using data from 2 prospective AMI registries (TRIUMPH and PREMIER), we identified patients for whom baseline and follow-up health status scores and documentation of CR participation (attendance of 1 or more sessions within 6 months post-AMI) were available. Health status was assessed by four Seattle Angina Questionnaire (SAQ) domain scores (quality of life [QoL], angina frequency [AF], treatment satisfaction [TS], and physical limitation [PL]), as well as SF-12 physical and mental health composite scores ( PCS & MCS ). We created propensity matched cohorts of CR participants and non-participants to examine the association between CR participation with health status (6 and 12 months) and all-cause mortality (up to 7 years), using conditional repeated measures and proportional hazards models, respectively. Results: Among 3,957 AMI patients from 31 sites, 2,015 patients (51%) participated in CR after discharge. Compared to non-participants, CR participants were more often Caucasian (83.6% vs. 65.4%), had higher rates of health insurance (90.6% vs. 79.3%), but clinically similar baseline SAQ and SF-12 scores in all domains. After propensity matching, all covariates were well-balanced (Standardized Difference <10 for all patient characteristics) between CR participants and non-participants. In the repeated measures analysis, the mean SAQ and SF-12 domain scores were clinically similar for both groups at 6 and 12 months after hospital discharge (Table). Using a conditional proportional hazards model, a decrease in all-cause mortality was noted in the CR participant group (HR 0.59, 95% CI [0.46, 0.75]). Conclusion: In a large, multi-center AMI cohort, we found that although CR participation seemed to improve survival, CR participants had similar health status improvements after AMI as non-participants. Further investigation is required to identify how CR programs can further maximize the health status benefits to post-AMI participants.
Abstract 208: Hospital Readmissions After Left Ventricular Assist Device Implantation
Haas, Lindsey R., Kushwaha, Sudhir S. , Grupper, Avishay , Shah, Nilay D., Dunlay, Shannon M. , Herrin, Jeph

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.208 Get It

Background: While implantation of left ventricular assist devices (LVAD) improves survival and quality of life in patients with advanced heart failure, very little is known about healthcare resource utilization, including hospital readmissions, post-LVAD. Methods: Administrative claims data from a large, national US health plan were used to identify privately insured and Medicare Advantage patients that received an LVAD (ICD-9-CM code 37.66) and survived to hospital discharge from January 1, 2006 through 31 August 31, 2013, and had at least six months coverage pre-LVAD. The individuals covered by this health plan, about 88 million in years 2003 to 2013, are geographically dispersed across the United States, with greatest representation in the South and Midwest census regions. Reasons for subsequent readmissions were categorized according to the AHRQ Clinical Classifications Software and risk factors for readmission analyzed using multiple failure Cox regression analysis. Patients were censored at the time of heart transplantation or end of coverage through November 30, 2013. Results: In total, 857 patients received an LVAD, of whom 693 (81%) survived to hospital discharge without undergoing heart transplantation (mean age 56 years, 77% male). After a median follow-up of 0.69 (interquartile range [IQR]: 0.31, 1.50) years, 1,659 readmissions occurred among 509 patients. Over this period, patients spent a median of 10.5 days (IQR: 0 -40 days) per followup year hospitalized. The number of readmissions per patient varied widely (0 to 20 per person), with 184 (26.6%) patients experiencing no readmissions, while 112 (16.2%) had 5 or more readmissions during follow-up. The most common reasons for readmission were device complications (291 readmissions in 155 patients), heart failure (246 readmissions in 135 patients), gastrointestinal bleeding (90 readmissions in 52 patients), and arrhythmia (88 readmissions in 55 patients). Readmission risk was higher in patients who had longer initial length of stay and more comorbid conditions. Discussion: There is tremendous variability in the readmission burden experienced post-LVAD, with some patients experiencing no readmissions while others are repeatedly hospitalized. LVAD therapy introduces a unique set of problems that often prompt readmission including device complications and gastrointestinal bleeding.
Abstract 172: Patients' Experiences from Symptom Onset to Initial Treatment for Atrial Fibrillation
McCabe, Pamela J. , Rhudy, Lori M. , DeVon, Holli A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.172 Get It

Background: The prevalence of atrial fibrillation (AF) is expected to increase 2.5-fold by 2050. As a result, there will be a greater demand for clinicians to provide patient education regarding the nature of AF and its management. Early self-management education is critical to provide patients with knowledge and skills they need to recognize AF, control its progression, and reduce associated complications of stroke and heart failure. Greater understanding of patients’ experiences from symptom onset through initial treatment for AF is needed to guide development of patient centered interventions to promote early effective self-management. Purpose: To describe patients’ experiences from symptom onset through initial treatment of AF. Methods: A descriptive qualitative design was used. Twenty females and 21 males at a Midwest academic medical center were interviewed using open-ended questions to explore their experiences from symptom onset through the initial treatment for AF. Data were analyzed using qualitative content analysis. Results: Participants’ mean age was 64.3 SD = 10.1 years. Themes emerging from data were: 1) understanding the meaning of symptoms 2) learning about AF 3) emotional response and 4) feeling cared for by healthcare providers. Participants were unacquainted with AF and took cues from providers’ responses to appraise their symptoms and diagnosis. Fear and uncertainty were reduced when providers initiated prompt treatment. Receiving clear, comprehensive information about AF was appreciated by participants and described as a factor in feeling cared for by providers. Conclusions: Providers’ played a critical role in reducing patients' emotional distress and helping them to develop an accurate understanding of AF symptoms and treatment. This study provides new insight into participant experiences from symptom onset through initial treatment of AF which may inform development of patient centered interventions to promote early effective AF self-management.
Abstract 141: Outcomes Associated with Temporarily Interrupting Anticoagulation in Outpatients with Atrial Fibrillation: Results from ORBIT-AF
Kim, Sunghee , Thomas, Laine , Kowey, Peter R. , Piccini, Jonathan P. , Ansell, Jack , Steinberg, Benjamin A. , Sherwood, Matthew W. , Gersh, Bernard J. , Fonarow, Gregg C. , Mahaffey, Kenneth W. , Peterson, Eric D.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.141 Get It

Background: Interruption of OAC is often required for invasive procedures, yet the frequency, management, and outcomes of temporary interruptions (TIs) in community practice are unknown. Methods: We assessed the frequency and reasons for TI in outpatients with AF enrolled in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). Patient characteristics and use of bridging anticoagulants were analyzed. Endpoints included periprocedural adverse events (bleeding, thrombotic, or other) and cause-specific hospitalization within 30 days after TI. Results: Overall 7,372 patients were treated with OAC at baseline; 30% (n=2200) required at least 1 TI during median follow-up of 1 year. Patients requiring TI were similar in age (mean age 74 for both) and CHADS2 scores (mean 2.4 for both) to those not requiring TI. Among 3104 interruptions, the most commonly-identified reasons were for non-cardiac surgery (n=827, 27%), followed by endoscopic procedures (n=551, 18%) and cardiac catheterization (n=308, 10%). Bridging anticoagulants were used in 23% (n=709) of interruptions, including low-molecular weight heparin (n=512) or unfractionated heparin (n=109). Rates of bridging were highest during cardiac surgery (44%), cardiac catheterization (32%), and catheter ablation (33%). Patients with a prior stroke or TIA were significantly more likely to receive bridging (35% vs. 25%, p=0.0003), however there was no difference between patients with CHADS2 score >=2 vs. 0-1 (27% vs. 25%, p=NS). Adverse events during interruption were more common in bridged patients (5.1% vs. 2.9%, p=0.02), including bleeding events (3.6% vs. 1.8%, p=0.02); thrombotic events were uncommon (0.7 [n=4] vs. 0.5% [n=10], p=NS). After interruption, adverse events occurred early in follow-up (Figure), and bridged patients were more likely to experience any adverse event (13% vs. 6.3%, p<0.0001), cardiovascular hospitalization (4.3% vs. 2.3%, p=0.02), and bleeding hospitalization (2.2% vs. 0.7%, p=0.002) within 30 days. Conclusions: Temporary interruptions are common in patients receiving OAC for AF, however, bridging anticoagulation is used in a minority. Bleeding events following TI occurred significantly more often in patients receiving bridging anticoagulation.
Abstract 13: The PCI Choice Decision Aid for Stable Angina: A Randomized Trial.
Coylewright, Megan , Dick, Sara, Shepel, Kathy, Zmolek, Becky, Askelin, Jason, Inselman, Jonathan , Shah, Nilay D. , Ting, Henry H. , Branda, Megan E. , Hess, Erik P. , LeBlanc, Annie , Montori, Víctor M.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 7 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.7.suppl_1.13 Get It

Background: Although percutaneous coronary intervention (PCI) has not been shown to reduce the risk of death and myocardial infarction (MI) for stable coronary artery disease (CAD), many patients believe that PCI is a life-saving procedure. PCI for stable CAD is known to improve patients’ quality of life more rapidly than medications alone. We conducted a randomized trial to assess the impact of a decision aid (DA) compared to usual care (UC) for the treatment of stable CAD when there is a choice between PCI and optimal medical therapy (OMT). Methods: The PCI Choice trial was a prospective, randomized trial comparing the effects of DA versus UC. The DA was designed with a user-centered approach for an in-visit consultation, involving patients and clinicians throughout the development process. The final DA included information on myocardial infarction (MI), death and quality of life outcomes for PCI with OMT vs. OMT alone in the treatment of stable angina, stratified by angina type. Risks of procedure, bleeding, stent thrombosis, and need for future procedures were also depicted. The primary outcome was patient knowledge, measured by pre- and post-visit surveys. Additional outcomes included decisional conflict, patient satisfaction, preferred decision making style, and treatment decision. Results: A total of 110 patients were enrolled; mean age was 68.3 years and 26% of patients were women. At baseline, most patients had CCS Class I/II angina and were on a mean of two anti-anginal medications (2.3, SD 1.2). Knowledge increased among patients receiving DA compared to UC (63% vs. 44% p=0.0003). Specific knowledge about the impact of PCI for stable angina on death and MI was higher in both groups compared to prior studies (54% DA, 46% UC, p=0.45; 12% prior). Patient satisfaction was significantly higher in the DA group vs. UC (72% vs 40%, p=0.004). Decisional conflict was greater than in non-procedural DA trials, and was not different between the two arms (p=.43). Following exposure to DA, patients’ preference for sharing decision making tended to change more with DA (55% to 65%) than with UC (56% to 59%). While the proportion of patients choosing PCI over OMT was nearly half in both groups, there were fewer patients that remained undecided with DA (18% vs. 4%; p=0.14 overall difference). Conclusions: Exposure to a DA for the choice of PCI vs. optimal medical therapy in stable CAD improved patient knowledge and satisfaction and decreased uncertainty, without reducing the rate of PCI. Use of the DA in a larger patient population may further delineate impact on outcomes such as treatment choice, geographic variation and cost.
Abstract 73: Effect Of A Lifestyle Improvement Program Using Cardiac Rehabilitation Resources On Metabolic Syndrome Components
Rodriguez-Escudero, Juan P., Somers, Virends, Heath, Amy, Squires, Ray W. , Lezlie, Johnson, Somers, Virend K. , Heath, Amy, Thomas, Randal J. , López-Jiménez, Francisco

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 5 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.5.suppl_1.a73 Get It

Objective We studied the effect of a lifestyle therapy program using the resources already available in a cardiac rehabilitation setting for patients at risk for metabolic syndrome (MetS). Methods We created a six-week cardiometabolic program (CMP) using facilities and resources of a cardiac rehabilitation setting. The CMP included a minimum of 6 once-a-week 60 min sessions consisting of exercise training and nutrition instruction, in addition to 6 once-a-week 60 min group behavioral modification classes following the LEARN program. We also assessed the outcomes in 239 patients (pts) who had at either obesity or hyperglycemia: 58 pts had enrolled and completed the CMP, 58 pts had signed up for the CMP but either never attended or dropped out early (Control 1) and had follow-up data, and 123 pts had not signed up for the CMP but had been seen in the outpatient preventive cardiology practice at the Mayo Clinic (Control 2). We compared changes in components of the MetS from baseline to six weeks (for the CMP group) and at 6 months for all pts. Results Of 187 people who signed up for the CMP, only 62 completed the program and from those, 58 gave authorization to use their clinical data in research. Of the 125 that never attended or dropped out early, 58 had follow-up data. Clinical characteristics of the CMP, Control 1, and Control 2 groups and improvement in each of the outcome measures are shown in the Table. In the CMP group, there was a significant improvement at 6 weeks in waist circumference, weight, diastolic blood pressure and total cholesterol. At 6 months the fasting glucose had also significantly improved. In contrast, improvements in Control 1 and Control 2 were modest at best. See Table. When comparing the 6 month changes in the CMP and Control 1, those in the CMP had more pronounced weight loss (-4.5±5 kg vs -0.14±6 kg, p<0.001); decrease in systolic blood pressure (-1.1±17 mmHg vs +9.6±20 mmHg, p=0.004); and decrease in diastolic blood pressure (-4.6±11 mmHg vs +3.4±15 mmHg, p=0.0017). Similarly, comparing CMP vs Control 2, a significantly greater drop in body weight (-4.5±5 kg vs -0.9±3 kg, p<0.001) and in diastolic blood pressure (-4.6±11 mmHg vs -0.7±9 mmHg, p=0.0202) was noted in the CMP. The change in the number of MetS components per patient dropped significantly, favoring the CMP group compared with the control groups. Conclusion A lifestyle therapy program for patients at risk for MetS can be implemented using existing resources of a cardiac rehabilitation program, although enrollment and completion rates are low. Such a program, however, is effective at improving cardiometabolic outcomes in individuals at risk for MetS.
Abstract 233: Patient Factors Minimally Impact Experience with Informed Consent Documents for Percutaneous Coronary Intervention
Coylewright, Megan , Gosch, Kensey , McNulty, Edward, Ting, Henry H. , Spertus, John A.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | March 20, 2022 | Volume: 5 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.5.suppl_1.a233 Get It

Background: In light of well-known deficiencies in the process of informed consent for percutaneous coronary intervention (PCI), we developed and tested a personalized consent form, PRISM; this was shown to improve patients' participation in the consent process, understanding of procedural risks, and engagement in shared decision-making when compared to original PCI consent forms. It is unknown whether patient factors traditionally known to impair the consent process, including socioeconomic status, literacy and numeracy, were associated with greater benefit from the PRISM consents. Methods: We interviewed 590 patients receiving original consent documents and 527 receiving PRISM consents and compared the rates of reviewing the consent form, recalling a risk of bleeding and engaging in discussions about stent type using hierarchical modified Poisson regression analysis. The interaction of patient factors (age, gender, education level, insurance status, literacy and numeracy) with PRISM on outcomes was assessed. Results: Overall, few patient characteristics were associated with outcomes, including review of consent forms, knowledge transfer, or engagement in shared decision-making (see Table), although older patients were less likely to discuss stent types with their doctors (RR=0.84/decade for original and 0.93/decade for PRISM). Those with more than a high school education were less likely to review original consents (RR=0.77; 95% CI=0.66, 0.89) compared to those with less education; this difference was eliminated with the PRISM consents (RR=1.0; 95%CI=0.82, 1.23; p-value for interaction = 0.01). Conclusions: PRISM consent forms led to improved participation in the consent process and knowledge transfer in a 9-center study; there was little variance by sociodemographic, economic, literacy or numeracy factors, both with original consents and with PRISM.